FDA 510(k) FDA class 2 Substantially Equivalent 🇺🇸 United States

23andMe Personal Genome Service (PGS) Pharmacogenetic Reports

K Number: K221885 · Decision Oct 26, 2022
Classifications
1
FEI Numbers
1
Registration Numbers
1
Same Product Code
2
Applicant Total
8
Review Days
119

Research this 510(k) in seconds

The Research Assistant summarizes clearance history, predicates and product-code trends — and cites every record.

Free to try · every answer cites its records

Basic Information

Device Name
23andMe Personal Genome Service (PGS) Pharmacogenetic Reports
K Number
K221885
Device Class
FDA class 2
Clearance Type
Traditional
Regulation Number
862.3364
Medical Specialty
Medical Genetics
Decision
Substantially Equivalent
Statement or Summary
Summary
Applicant
23AndMe, Inc.
Date Received
June 29, 2022
Decision Date
October 26, 2022
Product Code
QDJ
Advisory Committee
Medical Genetics
Review Advisory Committee
CH
Third Party
N

Classifications

This FDA 510(k) entry is associated with 1 FDA classification via its product code.

Product Code Device Name
QDJ Direct-To-Consumer Access Pharmacogenetic Assessment System

Similar 510(k) Clearances

Other 510(k) clearances with the same product code (QDJ), ordered by most recent decision date.

View all

Other Clearances by 23AndMe, Inc.

K Number Device Name
K223597 23andMe® Personal Genome Service® (PGS®) Genetic Health Risk Report for BRCA1/BRCA2 (Selected Variants)
K211499 23andMe PGS Genetic Risk Report for Hereditary Prostate Cancer (HOXB13-Related)
K193492 23andMe Personal Genome Service (PGS) Pharmacogenetic Reports
K182784 MUTYH-Associated Polyposis (MAP)
DEN180028 23andMe Personal Genome Service (PGS) Pharmacogenetic Reports
DEN170046 23andMe PGS Genetic Health Risk Report for BRCA1/BRCA2 (Selected Variants)
DEN160026 23andMe Personal Genome Service (PGS) Genetic Health Risk Test for Hereditary Thrombophilia